|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Krop IE, Winer EP. Ten years of HER2-directed therapy: Still questions after all these years. Breast Cancer Res Treat 2009;113(2):207-9. No abstract available
Krop IE et al. A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+ breast cancer. San Antonio Breast Cancer Symposium 2008;Abstract 3136.
Lin NU et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15(4):1452-9. Abstract
Lin NU et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26(12):1993-9. Abstract
O’Shaughnessy J et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Proc ASCO 2008;Abstract 1015.
Von Minckwitz G et al. Capecitabine vs capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05). Proc ASCO 2008;Abstract 1025.
 |
 |
EDITOR
Neil Love, MD
Edith A Perez, MD
- Select publications
Stephen E Jones, MD
- Select publications
Sandra M Swain, MD
- Select publications
Ian E Krop, MD, PhD
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
